# Silvia Novello

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/silvia-novello/

## Facts

| Field | Value |
| --- | --- |
| Citations | 49,325 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 86 |
| i10-index | 362 |
| Last Known Institution | University of Turin |
| OpenAlex ID | https://openalex.org/A5001428569 |
| ORCID iD | 0000-0001-7653-9748 |
| Works | 1,024 |

## Researcher papers

Showing 12 of 23.

- [Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-in-metastatic-non-small-cell-lung-cancer/)
- [Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-for-squamous-non-small-cell-lung-cancer/)
- [Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/metastatic-non-small-cell-lung-cancer-esmo-clinical-practice-guidelines-for/)
- [Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/metastatic-non-small-cell-lung-cancer-esmo-clinical-practice-guidelines-for-2/)
- [Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry](https://scholariq.org/papers/immune-checkpoint-inhibitors-for-patients-with-advanced-lung-cancer-and/)
- [Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/updated-analysis-from-keynote-189-pembrolizumab-or-placebo-plus-pemetrexed-and/)
- [Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer](https://scholariq.org/papers/perioperative-pembrolizumab-for-early-stage-non-small-cell-lung-cancer/)
- [Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial](https://scholariq.org/papers/docetaxel-plus-nintedanib-versus-docetaxel-plus-placebo-in-patients-with/)
- [Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial](https://scholariq.org/papers/dabrafenib-plus-trametinib-in-patients-with-previously-treated-brafv600e-mutant/)
- [Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial](https://scholariq.org/papers/chemotherapy-for-elderly-patients-with-advanced-non-small-cell-lung-cancer-the/)
- [Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-erlotinib-in-patients-with-untreated-egfr-mutated-advanced-non/)
- [Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/ceritinib-versus-chemotherapy-in-patients-with-alk-rearranged-non-small-cell/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [University of Turin](https://scholariq.org/institutions/university-of-turin/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.